Testing a new drug combo for stomach and other solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a certain amount of the HER2 protein (tested on a tumor sample).
- You must not have had trastuzumab deruxtecan (T-DXd) treatment before.
- You must be 18 or older and able to perform daily activities with little help (ECOG 0-1).
- You must have adequate organ function, like normal blood counts and kidney/liver function, within 7 days of starting.
- You cannot have active infections, certain lung conditions, or uncontrolled heart problems.
- You must avoid medications that affect a liver enzyme called CYP3A4, except for those given to prevent nausea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
This study tests a combination of an existing targeted drug (trastuzumab) and a new experimental drug (retlirafusp alfa) for advanced stomach cancer that has a specific marker (HER2) and did not respond to initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of new drugs given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it can shrink tumors and improve outcomes for patients whose cancer has certain markers.
Hear when a new Clinical Stage III Gastric Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.